# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Kaveri Pohlman maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $24 to $9.
HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target ...
Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $25 to ...
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.